tbuckley/cabot-search huggingface dataset:
Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies
Authors: Anna Maria Andersson, Julie Sølberg, Anders Koch, Lone Skov, Ivone Jakasa, Sanja Kezic, Jacob Pontoppidan Thyssen
Journal: Allergy (2021)

Abstract Background The cytokine profile of atopic dermatitis (AD) depends on age, ethnicity, and disease severity. This study examined biomarkers in children with AD collected by tape strips and skin biopsies, and examined whether the levels differed with filaggrin genotype, disease severity, and food allergy. Methods Twenty‐five children aged 2–14 years with AD were clinically examined. Skin biopsies were collected from lesional skin and tape strips were collected from lesional and non‐lesional skin. We analyzed natural moisturizing factor (NMF) and 17 immune markers represented by mRNA levels in skin biopsies and protein levels in tape strips. Common filaggrin gene mutations were examined in all children. Results The cytokine profile in lesional skin was dominated by a T helper (Th) 2 response in skin biopsies, and by a general increase in innate inflammation markers (interleukin (IL)‐1α, IL‐1β, IL‐8, IL‐18) along with TARC and CTACK in tape strips. The levels of TARC, CTACK, IL‐8, IL‐18 showed significant correlation with AD severity in both lesional and non‐lesional tape stripped skin, while no significant correlations were observed in skin biopsy data. In tape strips from lesional and non‐lesional skin, the levels of NMF and selected cytokines differed significantly between children with and without FLG mutations and food allergy. Conclusion Sampling of the stratum corneum with non‐invasive tape strips can be used to identify biomarkers that are associated with disease severity, food allergy and FLG mutations. Skin biopsies showed robust Th2 signature but was inferior for association analysis regarding severity.
難治性心室性不整脈の治療のための注入針高周波アブレーション【JST・京大機械翻訳】
Authors: G Stevenson William, B Tedrow Usha, Reddy Vivek, AbdelWahab Amir, Dukkipati Srinivas, M John Roy, Fujii Akira, Schaeffer Benjamin, Tanigawa Shinichi, Elsokkari Ihab, Koruth Jacob, Nakamura Tomofumi, Naniwadekar Aditi, Ghidoli Daniele, Pellegrini Christine, L Sapp John
Journal: Journal of the American College of Cardiology (2019)
Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden
Authors: Andrea Dehn-Hindenberg, Heike Saßmann, Verena Berndt, Torben Biester, Bettina Heidtmann, Norbert Jorch, Su-Jong Kim-Dorner, Katja Konrad, Eggert Lilienthal, Nicole Nellen-Hellmuth, Andreas Neu, Ralph Ziegler, Karin Lange
Journal: Diabetes Care (2021)

OBJECTIVE To investigate the occupational and financial consequences for parents following the onset of type 1 diabetes in their child. RESEARCH DESIGN AND METHODS A questionnaire assessing occupational and financial situations before and in the first year after the onset of diabetes was distributed to all families with a child ≤14 years of age at diagnosis with a diabetes duration of at least 12 months in nine German pediatric diabetes centers. RESULTS Data of 1,144 children (mean age at diagnosis 6.7 [3.6] years; 46.5% female) and their families were obtained. Mothers’ occupational status reflected in paid working hours was significantly reduced in the first year after their child's diabetes diagnosis (P &amp;lt; 0.001). Overall, 15.1% of mothers stopped working, and 11.5% reduced working hours. Mothers of preschool children were particularly affected. Fathers’ working status hardly changed (P = 0.75). Nearly half of the families (46.4%) reported moderate to severe financial losses. Compared with an earlier similar study in 2003, significant negative occupational consequences for mothers and financial burden on families remained unchanged in 2018 (P = 0.59 and 0.31, respectively). CONCLUSIONS Mothers of young children with newly diagnosed diabetes experienced negative consequences in their occupational situation. This inequality for mothers can have long-term negative consequences for their mental health and future economic situation. There is an urgent need for action to reduce the burden on families and to provide professional, social, and regulatory support, especially for mothers of young children with diabetes.
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
Authors: Patricia Rich, R Brian Mitchell, Eric Schaefer, Paul R Walker, John W Dubay, Jason Boyd, David Oubre, Ray Page, Mazen Khalil, Suman Sinha, Scott Boniol, Hafez Halawani, Edgardo S Santos, Warren Brenner, James M Orsini, Emily Pauli, Jonathan Goldberg, Andrea Veatch, Mitchell Haut, Bassam Ghabach, Savita Bidyasar, Maria Quejada, Waseemullah Khan, Kan Huang, Linda Traylor, Wallace Akerley
Journal: Journal for ImmunoTherapy of Cancer (2021)

Immune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was assessed for its ability to predict ICI therapy outcomes in this real-world, prospectively designed, observational study.The prospectively designed, observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) includes 35 US sites having enrolled over 3570 NSCLC patients at any stage and line of therapy. After enrolment and prior to therapy initiation, all patients are tested and designated HIC-Hot (HIC-H) or HIC-Cold (HIC-C). A prespecified interim analysis was performed after 1-year follow-up with the first 2000 enrolled patients. We report the overall survival (OS) of patients with advanced stage (IIIB and IV) NSCLC treated in the first-line (ICI-containing therapies n=284; all first-line therapies n=877), by treatment type and in HIC-defined subgroups.OS for HIC-H patients was longer than OS for HIC-C patients across treatment regimens, including ICI. For patients treated with all ICI regimens, median OS was not reached (95% CI 15.4 to undefined months) for HIC-H (n=196) vs 5.0 months (95% CI 2.9 to 6.4) for HIC-C patients (n=88); HR=0.38 (95% CI 0.27 to 0.53), p<0.0001. For ICI monotherapy, OS was 16.8 vs 2.8 months (HR=0.36 (95% CI 0.22 to 0.58), p<0.0001) and for ICI with chemotherapy OS was unreached vs 6.4 months (HR=0.41 (95% CI 0.26 to 0.67), p=0.0003). HIC results were independent of programmed death ligand 1 (PD-L1). In a subgroup with PD-L1 ≥50% and performance status 0-1, HIC stratified survival significantly for ICI monotherapy but not ICI with chemotherapy.Blood-based HIC proteomic testing provides clinically meaningful information for immunotherapy treatment decision in NSCLC independent of PD-L1. The data suggest that HIC-C patients should not be treated with ICI alone regardless of their PD-L1 expression.
Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris
Authors: Ingrid Morales, Ricardo Puertas-Avendaño, Alberto Sanchez, Adrian Perez-Barreto, Clara Rodriguez-Sabate, Manuel Rodriguez
Journal: Translational Neurodegeneration (2021)

The dopaminergic nigrostriatal neurons (DA cells) in healthy people present a slow degeneration with aging, which produces cellular debris throughout life. About 2%-5% of people present rapid cell degeneration of more than 50% of DA cells, which produces Parkinson's disease (PD). Neuroinflammation accelerates the cell degeneration and may be critical for the transition between the slow physiological and the rapid pathological degeneration of DA cells, particularly when it activates microglial cells of the medial forebrain bundle near dopaminergic axons. As synaptic debris produced by DA cell degeneration may trigger the parkinsonian neuroinflammation, this study investigated the removal of axonal debris produced by retrograde degeneration of DA cells, paying particular attention to the relative roles of astrocytes and microglia.Rats and mice were injected in the lateral ventricles with 6-hydroxydopamine, inducing a degeneration of dopaminergic synapses in the striatum which was not accompanied by non-selective tissue damage, microgliosis or neuroinflammation. The possible retrograde degeneration of dopaminergic axons, and the production and metabolization of DA-cell debris were studied with immunohistochemical methods and analyzed in confocal and electron microscopy images.The selective degeneration of dopaminergic synapses in the striatum was followed by a retrograde degeneration of dopaminergic axons whose debris was found within spheroids of the medial forebrain bundle. These spheroids retained mitochondria and most (e.g., tyrosine hydroxylase, the dopamine transporter protein, and amyloid precursor protein) but not all (e.g., α-synuclein) proteins of the degenerating dopaminergic axons. Spheroids showed initial (autophagosomes) but not late (lysosomes) components of autophagy (incomplete autophagy). These spheroids were penetrated by astrocytic processes of the medial forebrain bundle, which provided the lysosomes needed to continue the degradation of dopaminergic debris. Finally, dopaminergic proteins were observed in the cell somata of astrocytes. No microgliosis or microglial phagocytosis of debris was observed in the medial forebrain bundle during the retrograde degeneration of dopaminergic axons.The present data suggest a physiological role of astrocytic phagocytosis of axonal debris for the medial forebrain bundle astrocytes, which may prevent the activation of microglia and the spread of retrograde axonal degeneration in PD.
The Potential and Pitfalls of Coronary Artery Calcium Scoring
Authors: Sadiya S. Khan, Ann Marie Navar
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
TCT-404 Acute Heart Failure Hospitalizations Following Transcatheter Aortic Valve Replacement in the United States
Authors: Jayakumar Sreenivasan, Aaqib H. Malik, Katerina Jurkoshek, Muhammad Khan, Sreema Puthiya Parambath, Syed Zaid, Ziad Ali, Hasan Ahmad, Erin Michos, Robert Mentz, Sachin Goel
Journal: Journal of the American College of Cardiology (2021)
In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide
Authors: Gunjan Y. Gandhi
Journal: Annals of Internal Medicine (2021)

ACP Journal ClubNovember 2021In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutideGunjan Y. Gandhi, MD, MScGunjan Y. Gandhi, MD, MScUniversity of Florida College of Medicine, Jacksonville, Florida, USA (G.Y.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202111160-127 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationFrias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-15. https://pubmed.ncbi.nlm.nih.gov/34170647Clinical Impact RatingsGIM/FP/GP: Endocrinology: References1. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21. [PMID: 29364588] Google Scholar2. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-85. [PMID: 31422062] Google Scholar3. U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. Accessed at www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 on 31 Aug 2021. Google Scholar4. U.S. Food and Drug Administration. FDA approves weight management drug for patients aged 12 and older. Accessed at www.fda.gov/drugs/drug-safety-and-availability/fda-approves-weight-management-drug-patients-aged-12-and-older on 31 Aug 2021. Google Scholar5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989. [PMID: 33567185] Google Scholar6. Heimbürger SM, Bergmann NC, Augustin R, et al. Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides. 2020;125:170174. [PMID: 31689454] Google Scholar7. A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT). Accessed at https://clinicaltrials.gov/ct2/show/NCT04255433 on 31 Aug 2021. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Florida College of Medicine, Jacksonville, Florida, USA (G.Y.G.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-7322.This article was published at Annals.org on 2 November 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics November 2021Volume 174, Issue 11Page: JC127 ePublished: 2 November 2021 Issue Published: November 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A longitudinal study on symptom duration and 60-day clinical course in non-hospitalised COVID-19 cases in Berlin, Germany, March to May, 2020
Authors: Neil J. Saad, Felix Moek, Fabienne Steitz, Lukas Murajda, Till Bärnighausen, Thomas Zoller, Kirsten Pörtner, Nadine Muller
Journal: Eurosurveillance (2021)

Background Detailed information on symptom duration and temporal course of patients with mild COVID-19 was scarce at the beginning of the COVID-19 pandemic. Aim We aimed to determine the longitudinal course of clinical symptoms in non-hospitalised COVID-19 patients in Berlin, Germany. Methods Between March and May 2020, 102 confirmed COVID-19 cases in home isolation notified in Berlin, Germany, were sampled using total population sampling. Data on 25 symptoms were collected during telephone consultations (a maximum of four consultations) with each patient. We collected information on prevalence and duration of symptoms for each day of the first 2 weeks after symptom onset and for day 30 and 60 after symptom onset. Results Median age was 35 years (range 18–74), 57% (58/102) were female, and 37% (38/102) reported having comorbidities. During the first 2 weeks, most common symptoms were malaise (94%, 92/98), headache (71%, 70/98), and rhinitis (69%, 68/98). Malaise was present for a median of 11 days (IQR 7–14 days) with 35% (34/98) of cases still reporting malaise on day 14. Headache and muscle pain mostly occurred during the first week, whereas dysosmia and dysgeusia mostly occurred during the second week. Symptoms persisted in 41% (39/95) and 20% (18/88) of patients on day 30 and 60, respectively. Conclusion Our study shows that a significant proportion of non-hospitalised COVID-19 cases endured symptoms for at least 2 months. Further research is needed to assess the frequency of long-term adverse health effects in non-hospitalised COVID-19 patients.
Abstract 791: A Critical Role for Bmper (BMP-binding Endothelial cell precursor-derived Regulator) in Cardiac Muscle Mass Regulation during Development and Pressure Overload Induced Hypertrophy
Authors: Monte Willis, Rongqin Ren, Cam Patterson
Journal: Circulation (2007)

Bone morphogenetic proteins (BMPs) of the TGF-beta superfamily, have been implicated in multiple processes during cardiac development. Our laboratory recently described an unprecedented role for Bmper in antagonizing BMP-2, BMP-4, and BMP-6. To determine the role of Bmper on cardiac development in vivo, we created Bmper null (Bmper −/−) mice by replacing exons 1 and 2 with GFP. Since Bmper −/− mice are perinatally lethal, we determined pre-natal cardiac function of Bmper −/− mice in utero just before birth. By echocardiography, E18.5 Bmper −/− embryos had decreased cardiac function (24.2 +/− 8.1% fractional shortening) compared to Bmper +/− and Bmper +/+ siblings (52.2 +/− 1.6% fractional shortening) (N=4/group). To further characterize the role of Bmper on cardiac function in adult mice, we performed echocardiography on 8-week old male and female Bmper +/− and littermate control Bmper +/+. Bmper +/− mice had an approximately 15% decrease in anterior and posterior wall thickness compared to sibling Bmper +/+ mice at baseline (n=10/group). Cross-sectional areas of Bmper +/− cardiomyocytes were approximately 20% less than wild type controls, indicating cardiomyocyte hypoplasia in adult Bmper +/− mice at baseline. Histologically, no significant differences were identified in representative H&amp;E and trichrome stained adult Bmper +/− and Bmper +/+ cardiac sections at baseline. To determine the effects of Bmper expression on the development of cardiac hypertrophy, both Bmper +/− and Bmper +/+ sibling controls underwent transaortic constriction (TAC), followed by weekly echocardiography. While a deficit was identified in Bmper +/− mice at baseline, both anterior and posterior wall thicknesses increased after TAC, such that identical wall thicknesses were identified in Bmper +/− and Bmper +/+ mice 1–4 weeks after TAC. Notably, cardiac function (fractional shortening %) and histological evaluation revealed no differences between Bmper +/− and Bmper +/+ any time after TAC. These studies identify for the first time that Bmper expression plays a critical role in regulating cardiac muscle mass during development, and that Bmper regulates the development of hypertrophy in response to pressure overload in vivo.
Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Yue Cao, Catherine T. Haring, Collin Brummel, Chandan Bhambhani, Madhava Aryal, Choonik Lee, Molly Heft Neal, Apurva Bhangale, Wenjin Gu, Keith Casper, Kelly Malloy, Yilun Sun, Andrew Shuman, Mark E. Prince, Matthew E. Spector, Steven Chinn, Jennifer Shah, Caitlin Schonewolf, Jonathan B. McHugh, Ryan E. Mills, Muneesh Tewari, Francis P. Worden, Paul L. Swiecicki, Michelle Mierzwa, J. Chad Brenner
Journal: Clinical Cancer Research (2021)

Abstract Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with tumor progression after chemoradiation, and (ii) to compare the predictive value of ctDNA to imaging biomarkers of MRI and FDG-PET. Experimental Design: Serial blood samples were collected from patients with AJCC8 stage III OPSCC (n = 34) enrolled on a randomized trial: pretreatment; during chemoradiation at weeks 2, 4, and 7; and posttreatment. All patients also had dynamic-contrast-enhanced and diffusion-weighted MRI, as well as FDG-PET scans pre-chemoradiation and week 2 during chemoradiation. ctDNA values were analyzed for prediction of freedom from progression (FFP), and correlations with aggressive tumor subvolumes with low blood volume (TVLBV) and low apparent diffusion coefficient (TVLADC), and metabolic tumor volume (MTV) using Cox proportional hazards model and Spearman rank correlation. Results: Low pretreatment ctDNA and an early increase in ctDNA at week 2 compared with baseline were significantly associated with superior FFP (P &amp;lt; 0.02 and P &amp;lt; 0.05, respectively). At week 4 or 7, neither ctDNA counts nor clearance were significantly predictive of progression (P = 0.8). Pretreatment ctDNA values were significantly correlated with nodal TVLBV, TVLADC, and MTV pre-chemoradiation (P &amp;lt; 0.03), while the ctDNA values at week 2 were correlated with these imaging metrics in primary tumor. Multivariate analysis showed that ctDNA and the imaging metrics performed comparably to predict FFP. Conclusions: Early ctDNA kinetics during definitive chemoradiation may predict therapy response in stage III OPSCC.
TCT-105 Impact of Pulmonary Hypertension Differentiation on the Outcome of Patients Undergoing MitraClip Therapy
Authors: Tobias Schmidt, Timm Ubben, Buntaro Fujita, Roman Pfister, Hannes Alessandrini, Karl-Heinz Kuck, Stephan Willems, Ingo Eitel, Christian Frerker
Journal: Journal of the American College of Cardiology (2021)
TCT-201 Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention
Authors: Masafumi Ono, Yoshinobu Onuma, Hideyuki Kawashima, Hironori Hara, Chao Gao, Rutao Wang, Neil O’Leary, Scot Garg, Peter Juni, Christian Hamm, Marco Valgimigli, Stephan Windecker, Pascal Vranckx, Efthymios Deliargyris, Deepak Bhatt, Robert Storey, Patrick Serruys
Journal: Journal of the American College of Cardiology (2021)
Government ministers not wearing masks was bad enough, but their defence of this position is even worse
Authors: Stephen Reicher, John Drury, Ann Phoenix, Elizabeth Stokoe
Journal: BMJ (2021)

At a press conference on 20 October 2021, the secretary of state for health and social care Sajid Javid repeatedly urged the public to comply with voluntary covid measures in England, notably wearing masks in crowded indoor spaces.He warned that failure to do so would "hit us all" and "make it more likely we're going to have more restrictions.
Every step counts: synthesising reviews associating objectively measured physical activity and sedentary behaviour with clinical outcomes in community-dwelling older adults
Authors: Keenan A Ramsey, Carel G M Meskers, Andrea B Maier
Journal: The Lancet Healthy Longevity (2021)

It is unclear which parameters of physical activity and sedentary behaviour are important for healthy ageing, and to what extent. This Review aimed to synthesise, quantify, and compare the strength of the associations between physical activity and sedentary behaviour with clinically relevant outcomes. Systematic reviews describing community-dwelling adults older than 60 years and reporting standardised associations of objectively measured physical activity and sedentary behaviour with mortality, activities of daily living, frailty, falls and fear of falling, muscle strength and power, and global cognition, were included. Standardised associations were expressed as standardised regression coefficients (βs) and compared within and across outcome domains. Six systematic reviews were included with sample sizes ranging from 7696 to 43 796 (mean or median age 60–92 years). Higher physical activity and lower sedentary behaviour were most strongly associated with better chair stand test performance and lower body muscle strength, and least with falls and hand grip strength. Number of steps was the most strongly and most consistently associated with clinical outcomes. Conferring to a wide array of positive outcomes, steps provide a clinically relevant target that shows practical ease. Future recommendations should promote steps regardless of ability, encouraging that some physical activity is better than none, or, as the present findings show, that every step counts.